Innovative Medicines Initiative
GPTKB entity
Statements (56)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Partnerships
|
gptkbp:addresses |
rare diseases
chronic diseases infectious diseases |
gptkbp:aims_to |
foster innovation
enhance competitiveness improve health reduce time to market for new medicines accelerate patient access to therapies |
gptkbp:collaborates_with |
gptkb:pharmaceuticals
gptkb:European_Commission |
gptkbp:contributes_to |
European health research
|
gptkbp:develops |
new methodologies
|
gptkbp:encourages |
collaborative research
patient involvement |
gptkbp:enhances |
drug development processes
|
gptkbp:facilitates |
data sharing
|
gptkbp:focuses_on |
research and development
|
gptkbp:founded |
gptkb:2008
|
gptkbp:funding |
1.7 billion euros
|
gptkbp:has_impact_on |
public health
healthcare systems |
gptkbp:has_partnerships_with |
academic institutions
regulatory bodies biotech companies patient organizations |
gptkbp:has_project |
gptkb:IMI2
IMI1 |
gptkbp:headquartered_in |
gptkb:Brussels
|
https://www.w3.org/2000/01/rdf-schema#label |
Innovative Medicines Initiative
|
gptkbp:involves |
stakeholders
|
gptkbp:is_evaluated_by |
independent experts
|
gptkbp:is_involved_in |
clinical trials
personalized medicine big data analytics biomedical research vaccine development digital health solutions health technology assessment healthcare innovation regulatory science |
gptkbp:is_part_of |
gptkb:Horizon_2020
EU health initiatives |
gptkbp:is_recognized_by |
gptkb:European_Union
healthcare stakeholders |
gptkbp:is_supported_by |
gptkb:European_Medicines_Agency
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations research organizations various universities |
gptkbp:operates_in |
gptkb:Europe
|
gptkbp:promotes |
public-private collaboration
|
gptkbp:provides |
funding opportunities
|
gptkbp:supports |
innovative healthcare solutions
|
gptkbp:bfsParent |
gptkb:Blueprint_Medicines
gptkb:Vertex_Pharmaceuticals |
gptkbp:bfsLayer |
4
|